UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1453-1
Program Prior Authorization/Notification
Medication Duvyzat™ (givinostat) oral suspension
P&T Approval Date 7/2024
Effective Date 10/1/2024
1. Background:
Duvyzat (givinostat) is a histone deacetylase inhibitor indicated for the treatment of Duchenne
muscular dystrophy (DMD) in patients 6 years of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Duvyzat will be approved based upon both of the following criteria:
a. Diagnosis of Duchenne muscular dystrophy (DMD)
-AND-
b. Patient is 6 years of age or older
Authorization will be issued for 12 months.
B. Reauthorization
1. Duvyzat will be approved based on the following criterion:
a. Documentation of positive clinical response to Duvyzat therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
© 2024 UnitedHealthcare Services, Inc.
1
4. Reference:
1. Duvyzat [package insert]. Concord, MA: ITF Therapeutics, LLC; March 2024.
Program Prior Authorization/Notification - Duvyzat (givinostat)
Change Control
7/2024 New program
© 2024 UnitedHealthcare Services, Inc.
2